Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study
07 Dezember 2023 - 1:49PM
Dow Jones News
By Colin Kellaher
Merck & Co. is ending a late-stage study of the combination
of Keytruda and Lynparza in certain lung cancer patients due to an
expected failure of the trial.
The Rahway, N.J., drugmaker, which was evaluating Keytruda in
combination with maintenance Lynparza in a Phase 3 study in
patients with metastatic squamous non-small cell lung cancer, said
it is stopping the trial for futility based on the recommendation
of an independent data monitoring committee.
Merck said a third interim study analysis showed that Keytruda
in combination with chemotherapy followed by Keytruda plus Lynparza
didn't demonstrate an improvement in overall survival, one of the
study's dual primary endpoints, compared to Keytruda in combination
with chemotherapy followed by Keytruda plus placebo.
The study's other dual primary endpoint, which measured how long
the patient lived without the disease worsening, wasn't
statistically significant at the second interim analysis.
Merck is studying Keytruda, a cancer drug that harnesses a
patient's immune system to fight tumors, in a raft of trials across
a wide variety of cancers and treatment settings. The company
jointly develops and commercializes Lynparza with AstraZeneca.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 07, 2023 07:34 ET (12:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
